Cole-Parmer Acquires Quality Control Standards Manufacturer ZeptoMetrix

Jan 13, 2021

|

NEW YORK — Private equity firm GTCR said on Tuesday that its Cole-Parmer business has acquired ZeptoMetrix, a maker of quality control standards and verification panels used in infectious disease molecular diagnostic testing.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Worries About Increased Deadliness

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Merck Stops SARS-CoV-2 Vaccine Development

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

Featured White Papers

For In Vitro Diagnostic Materials: Efficacy vs. Thimerosal and Sodium Azide

Development of a Quantitative Lateral Flow Test Using Estapor Europium Microspheres

Performance of Estapor Microspheres and Hi-Flow Plus Membranes in a Lateral Flow Assay for Human Chorionic Gonadotropin (hCG)

ProClin 300 Preservative An In-depth Technical Analysis

Feb

11

Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb

17

Featured Webinar

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.

Feb

18

Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression.

Feb

23

Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.

Menu

Cole-Parmer Acquires Quality Control Standards Manufacturer ZeptoMetrix

To read the full story....

Breaking News

Hypertrophic Cardiomyopathy Studies Reveal Common Contributors, Risk Score

Machine Learning Tool Uncovers Novel Endogenous Viruses in Human Genome

Todos Medical Obtains $3.4M Investment From Yozma Group Korea

Infectious Disease Test Firm Talis Biomedical Files for IPO

Sano Genetics Raises £2.5M in Private Seed Funding

Top Five Articles on GenomeWeb Last Week: Thermo Fisher Scientific, Illumina, Lucira Health, and More

The Scan

Should Also Work

Worries About Increased Deadliness

Merck Stops SARS-CoV-2 Vaccine Development

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

Featured White Papers

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Single-Cell Multiomics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Infectious Disease Test Firm Talis Biomedical Files for IPO

NeoGenomics to Boost Growth of Pharma, Informatics Divisions Through CDx Agreements, Acquisitions

Caris Shares Data for AI-Driven Tumor Origin Prediction, Hinting at Diagnostic, Patient Benefit

Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

Sponsorships